Skip to main content

Macular Degeneration clinical trials at UCSD
2 in progress, 1 open to eligible people

  • Extension Study for the Port Delivery System With Ranibizumab (Portal)

    open to eligible people ages 50 years and up

    This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 (Ladder) or Phase III Study GR40548 (Archway).

    La Jolla, California and other locations

  • A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

    Sorry, accepting new patients by invitation only

    This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD). The global enrollment phase has closed, but participants are still being recruited only at sites in Japan.

    La Jolla, California and other locations

Last updated: